胰高糖素样多肽-1及受其体激动剂对2型糖尿病心血管病变的影响
被引量:4
摘要
随着人民生活水平的提高,我国2型糖尿病(T2DM)的患病率逐年上升,因糖尿病并发症而死亡的人数也逐年增多,其中,心血管并发症是T2DM患者的主要死亡原因。作为治疗T2DM的新药——胰高糖素样多肽-1(GLP-1)及其受体激动剂最近备受关注。研究表明,GLP-1受体激动剂不仅能够刺激胰岛素分泌、抑制胰高糖素分泌,减少肝糖输出,改善外周组织对胰岛素的敏感性,延缓胃排空,抑制食欲及摄食,
出处
《中国临床医生杂志》
2015年第3期23-26,共4页
Chinese Journal For Clinicians
参考文献21
-
1Russell-Jone D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[ J 1. Mol Cell Endo- crinol,2009 (297) :137-140.
-
2Knudsen LB, Knudsen SM, Wilken M, et al. Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its ef- ficacy[J]. Diabetes,2003(52) :A321-322.
-
3Rodbard HW, Blonde L, Braithwaite SS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitue [J]. Endocr Praet,2007 ( 13 ) : 1-68.
-
4黄新梅,刘军.肠促胰岛素相关药物的临床作用研究进展[J].上海医药,2013,34(7):7-10. 被引量:4
-
5张艳,李伟.利拉鲁肽对人脐静脉内皮细胞中核转录因子κB和单核细胞趋化蛋白1表达的影响[J].中国现代医学杂志,2013,23(6):29-33. 被引量:2
-
6Liu H, Dear AE, Knucsen LB, et al. A long-acting glucagon-like pep- tide-1 analogue attenuates induction of plasminogen activator inhibi- tor type-1 and vascular adhesion molecules [ J ]. J Endocrinol, 2009 (201) :59-66.
-
7Bunck MC,Comer A,Eliasson B, et al. One-year treatment with ex- enatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress [ J ]. Atherosclerosis, 2010,212 ( 1 ) : 223 -229.
-
8Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on sys- tolic blood pressure in subjects with type 2 diabetes [ J ]. Am J Hy- pertens,2010(23) :334-339.
-
9Nauck M,Frid A,Hermansen K,et al. Efficacy and safety compari- son of liraglutide, glimepiride, and placebo, all in combination with metformin,in type 2 diabetes : the LEAD ( liraglutide effect and ac- tion in diabetes ) -2 study [J]. Diabetes Care, 2009 ( 3 ) :84- 90.
-
10Zinman B, Gerieh J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met- formin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD) [J]. Diabetes Care ,2009 ( 32 ) :1224-1230.
二级参考文献41
-
1高虹,宁光.胰高血糖素样肽1的胰腺外作用研究进展[J].国际内科学杂志,2007,34(7):408-411. 被引量:25
-
2Raun K,Von VP,Gotfredsen CF,et al. Liraglutide,a long-acting glucagon- like peptide-1 analog,reduces body weight and food intake in obese candy-fed rats,whereas a dipeptidyl peptidase-IV inhibitor,vildagliptin, does not [J]. Diabetes, 2007,56 : 8-15.
-
3Sarruf DA,Thaler JP,Morton GJ,et al. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats [J]. Diabetes,2010,59:1817-1824.
-
4Yie J,Hecht R,Patel J,et al. FGF21 N-and C-termini play different roles in receptor interaction and activation [J]. Febs Lett,2009,583:19- 21.
-
5Zhang X,Yeung DC,Karpisek M,et al. Serum FGF-21 levies are increased in obesity and independently associated with the metabolic syndrome in humans [J]. Diabetes,2008,57:1246-1253.
-
6Elrick H, Stimmler L, Hlad C J, et al. Plasma insulin response to oral and intravenous glucose administration [J]. J Clin Endocrinol Metab,1964, 24(10): 1076-1082.
-
7Hoist J J, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus [J]. Mol Cell Endocrinol, 2009, 297(1-2): 127-136.
-
8Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? [J]. Diabetes, 2007, 56(8): 1951-1959.
-
9Nauck MA, Heimesaat MM, Hoist JJ. Preserved incretin activity of glucagon-like peptide 1 but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus [J]. J Clin Invest, 1993, 91(1): 301-307.
-
10Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review [J]. Clin Ther, 2012, 34(6): 1247-1258.
共引文献8
-
1李微,张涛,李瑞生,安星兰,王志红,刘源.n-3、n-6PUFA高脂饮食对SD大鼠肝脏胆固醇合成相关基因表达影响[J].中国实验动物学报,2013,21(4):26-29. 被引量:2
-
2李国娟,陈宏,董艳华,涂晶,洪涛,于化鹏.利拉鲁肽对促动脉粥样硬化饮食喂养大鼠大动脉的保护作用及对肝脏PGC-1α表达的影响![J].华中科技大学学报(医学版),2014,43(6):653-657. 被引量:2
-
3赵富利,亓民,刘辉.利拉鲁肽联合二甲双胍治疗2型糖尿病伴肥胖患者疗效及对微炎症状态的影响[J].中国现代医学杂志,2015,25(15):43-46. 被引量:78
-
4韩蕊,徐志芳,祁范范,雷营,杨昱,石志平,刘岩,周亚茹.2型糖尿病大鼠胸主动脉磷酸化p38丝裂素活化蛋白激酶蛋白表达及利拉鲁肽对其干预作用的研究[J].中国糖尿病杂志,2016,24(6):556-560. 被引量:8
-
5郭洁,孙耀东,边亚,牛素贞,王丽娜.观察利拉鲁肽对糖尿病病人血脂和超敏C-反应蛋白的影响[J].中西医结合心脑血管病杂志,2016,14(17):2055-2057. 被引量:5
-
6王振华,陈泽龙,潘德顺.沙格列汀与阿卡波糖治疗二甲双胍控制不佳Ⅱ型糖尿病患者的临床疗效观察[J].中国药物经济学,2018,13(1):34-36. 被引量:2
-
7计成,王超,叶晶晶,刘慧.2016~2018年南京地区肠促胰素类药物利用情况分析[J].药物流行病学杂志,2020,29(5):327-331. 被引量:3
-
8李杰,杨海梅,宋秀道,江国荣.苦味中药激活肠道苦味受体分泌胰高血糖素样肽-1的研究现状[J].中国临床药理学杂志,2021,37(2):179-182. 被引量:5
同被引文献43
-
1王育璠,彭永德.胰高血糖素样肽-1——2型糖尿病治疗的新策略[J].世界临床药物,2004,25(12):718-721. 被引量:4
-
2中华医学会糖尿病学分会.中国2型糖尿病防治指南/2010年版[M].北京:北京大学医学出版社,2011:5.
-
3Stolar M. Glycemic control and complications in type 2 diabetes mel- litus[J]. Am J Med,2010,123(3) :1-11.
-
4Forte GI, Pi[ato G, Vaccarino I, et al. Risk profiles in type 2 diabe- tes (metabolic syndrome) : indentify vascular damages related com- plications EJ]- Curr Pharm Des, 2010, 16(7) :898-903.
-
5Azcutia V, Abu-Taha M, Romacho T, et al. Inflammation deter- mines the proadhesive properties of high extracellular D-glucose in human endothelial cells in vitro and rat microvessels in vivo [ J ]. PLoS One, 2010, 5(4) :el0091.
-
6Hanai K, Babazono T, Yoshida N, et al. Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients [ J]. Nephrol Dial Trans- plant, 2012, 27(3) :1070-1075.
-
7Ahr6n B. GLP-1 for type 2 diabetes [J].Exp Cell Res,2011,317(9): 1239.
-
8Donnelly D. The structure and function of the glucagon-like peptide- 1 receptor and its ligands[J].Br J Pharmacol,2012,166( 1):27.
-
9Purves G I, Kamishima T, Davies L M, et al. Exchange protein activated by cAMP (Epac) mediates cAMP-dependent but protein kinase A-insensitive modulation of vascular ATP-sensitive Potassium channels[J].J Physiol,2009,587(Pt 14):3639.
-
10Furman B, Ong W K, Pyne N J. Cyclic AMP signaling in pancreatic islets[J].Adv Exp Med Biol,2010,654:281.
引证文献4
-
1李慧英.糖尿病患者心血管事件危险因素的临床分析[J].中国临床医生杂志,2015,43(6):52-53. 被引量:10
-
2林松峰,张瑞,王丹丹,郭刚.体外表达GLP-1多拷贝的最优条件研究[J].天津医科大学学报,2015,21(5):388-392.
-
3白小岗,李霞,徐杰.胰高血糖素样肽-1受体激动剂对2型糖尿病患者血脂的影响[J].临床内科杂志,2017,34(4):277-278.
-
4贾敏,易继涛,王从平,刘群会.T2DM合并CI患者血清趋化素水平的变化及临床意义[J].西南国防医药,2019,29(5):570-572. 被引量:2
二级引证文献12
-
1方俪鹃,赵雪惠,刘晓可,富晓旭,周秀娟,李玲玲.糖尿病心血管病变危险因素与伏邪探析[J].中医学报,2018,33(12):2313-2315. 被引量:4
-
2李玉,段敬柱.心理应激对冠心病合并2型糖尿病患者PCI术后糖代谢、胰岛素抵抗及炎症介质水平的影响[J].中国健康心理学杂志,2019,27(1):89-92. 被引量:15
-
3宁丽萍,王庆莅,王占科,郭靓,赵婉茹.糖尿病合并尿路感染患者尿液细菌培养及药物敏感试验分析[J].解放军医药杂志,2015,27(12):78-81. 被引量:20
-
4王丽娟,赵翠伶,付佐娣,王连英,张雅静,李玉凤.城郊糖尿病及前期流行现状分析[J].中国临床医生杂志,2016,44(4):35-38. 被引量:10
-
5周静,高晟,吴深涛.糖尿病周围血管病变中医证候规律探析[J].中国实验方剂学杂志,2016,22(17):136-140. 被引量:13
-
6马志刚,左庆瑶.中老年糖尿病合并高血压患者心脑血管事件发生情况分析[J].中国医药,2017,12(9):1306-1309. 被引量:23
-
7邬春晓.血塞通注射液治疗糖尿病周围血管病变疗效分析[J].实用中西医结合临床,2017,17(8):67-68. 被引量:2
-
8王静悦,彭延波,孙博,王大力,张江,柴海霞.急性脑梗死并发应激性高血糖的危险因素分析及对认知预后的影响[J].中国综合临床,2020,36(6):513-519. 被引量:17
-
9刘佳.血清趋化素、25羟基维生素D在肌少症合并糖尿病患者中的表达及意义[J].检验医学与临床,2022,19(3):396-398. 被引量:9
-
10曾海波,周登峰,张荣.血清内脂素、趋化素预测老年急性缺血性脑卒中患者预后的价值[J].新疆医学,2022,52(4):419-421. 被引量:3
-
1王昱,郭晓蕙,姜崴.重组人胰高糖素样多肽-1(7-36)对胰岛β细胞分泌功能影响的实验研究[J].中国临床药理学杂志,2006,22(4):280-283.
-
2张凤平.胰高糖素样多肽1与代谢综合征的相关性研究[J].实用糖尿病杂志,2015,11(5):16-18.
-
3顾迁,高鑫.重组人胰高糖素样多肽-1对GK大鼠体重、糖代谢、β细胞功能及团块量的影响[J].复旦学报(医学版),2007,34(1):111-115.
-
4陈琳,肖长青.胰高糖素样多肽-1(GLP-1)及其类似物用于2型糖尿病治疗的研究进展[J].内科,2009,4(2):263-265.
-
5于征,冯建华.单纯性肥胖患者血清抵抗素与胰高糖素样多肽-1及胰岛素的相关性[J].广东医学,2010,31(10):1316-1317.
-
6陆鸣,夏宁.胰高糖素样多肽-1与糖尿病[J].国外医学(内科学分册),2005,32(9):372-374.
-
7魏华,毛睿睿,陈红霞,冯维斌.2型糖尿病胰岛素抵抗的中医药研究进展[J].光明中医,2004,19(6):37-39. 被引量:6
-
8丁慧,袁迎霞.吡格列酮对高血压肥胖患者的降压作用[J].河北医药,2013,35(20):3127-3128.
-
9吴鸿,邹大进.糖尿病新药应用进展[J].中国实用内科杂志,2009,29(10):962-963. 被引量:6
-
10Amanda I Adler,Elizabeth J Shaw,Tim Stokes,Francis Ruiz,包玉倩(译).2型糖尿病血糖控制新药:英国国家卫生和临床医疗优选研究所指南概要[J].英国医学杂志中文版,2009,12(5):312-313.